CD3 monitoring and thymoglobulin therapy in cardiac transplantation: Clinical outcomes and pharmacoeconomic implications

Walter E. Uber, L. A. Uber, A. B. VanBakel, A. J. Crumbley, Naveen Luke Pereira, J. S. Ikonomidis, D. S. Feldman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction. CD3 monitoring of antithymocyte globulin therapy in renal transplantation has been shown to be more cost-effective than standard regimens. The objective of this study was to evaluate CD3 monitoring with Thymoglobulin in cardiac transplantation. Methods. Cardiac transplant patients who required antithymocyte globulin therapy were dose-adjusted to maintain absolute CD3 counts <25 cells/μL. Endomyocardial biopsies and hemodynamic parameters were used to assess efficacy. The incidences of hematological side effects, opportunistic infections, and malignancies were recorded; in addition we performed a cost comparison. Results. Eight patients were treated with Thymoglobulin using CD3 monitoring to adjust the dosing. All patients responded with few side effects. Compared to standard dosing, CD3 monitoring allowed a 60% reduction in the average total dose and a 58% reduction in cost per patient. Conclusion. CD3 monitoring of Thymoglobulin therapy in cardiac transplant patients results in lower doses and reduced costs with equivalent efficacy and a low incidence of complications.

Original languageEnglish (US)
Pages (from-to)3245-3249
Number of pages5
JournalTransplantation Proceedings
Volume36
Issue number10
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Pharmaceutical Economics
Heart Transplantation
Costs and Cost Analysis
Antilymphocyte Serum
Transplants
Therapeutics
Incidence
Opportunistic Infections
Kidney Transplantation
Hemodynamics
thymoglobulin
Biopsy
Neoplasms

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

CD3 monitoring and thymoglobulin therapy in cardiac transplantation : Clinical outcomes and pharmacoeconomic implications. / Uber, Walter E.; Uber, L. A.; VanBakel, A. B.; Crumbley, A. J.; Pereira, Naveen Luke; Ikonomidis, J. S.; Feldman, D. S.

In: Transplantation Proceedings, Vol. 36, No. 10, 2004, p. 3245-3249.

Research output: Contribution to journalArticle

Uber, Walter E. ; Uber, L. A. ; VanBakel, A. B. ; Crumbley, A. J. ; Pereira, Naveen Luke ; Ikonomidis, J. S. ; Feldman, D. S. / CD3 monitoring and thymoglobulin therapy in cardiac transplantation : Clinical outcomes and pharmacoeconomic implications. In: Transplantation Proceedings. 2004 ; Vol. 36, No. 10. pp. 3245-3249.
@article{f21fbf2d108947588c140595ef63a2f4,
title = "CD3 monitoring and thymoglobulin therapy in cardiac transplantation: Clinical outcomes and pharmacoeconomic implications",
abstract = "Introduction. CD3 monitoring of antithymocyte globulin therapy in renal transplantation has been shown to be more cost-effective than standard regimens. The objective of this study was to evaluate CD3 monitoring with Thymoglobulin in cardiac transplantation. Methods. Cardiac transplant patients who required antithymocyte globulin therapy were dose-adjusted to maintain absolute CD3 counts <25 cells/μL. Endomyocardial biopsies and hemodynamic parameters were used to assess efficacy. The incidences of hematological side effects, opportunistic infections, and malignancies were recorded; in addition we performed a cost comparison. Results. Eight patients were treated with Thymoglobulin using CD3 monitoring to adjust the dosing. All patients responded with few side effects. Compared to standard dosing, CD3 monitoring allowed a 60{\%} reduction in the average total dose and a 58{\%} reduction in cost per patient. Conclusion. CD3 monitoring of Thymoglobulin therapy in cardiac transplant patients results in lower doses and reduced costs with equivalent efficacy and a low incidence of complications.",
author = "Uber, {Walter E.} and Uber, {L. A.} and VanBakel, {A. B.} and Crumbley, {A. J.} and Pereira, {Naveen Luke} and Ikonomidis, {J. S.} and Feldman, {D. S.}",
year = "2004",
doi = "10.1016/j.transproceed.2004.11.099",
language = "English (US)",
volume = "36",
pages = "3245--3249",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - CD3 monitoring and thymoglobulin therapy in cardiac transplantation

T2 - Clinical outcomes and pharmacoeconomic implications

AU - Uber, Walter E.

AU - Uber, L. A.

AU - VanBakel, A. B.

AU - Crumbley, A. J.

AU - Pereira, Naveen Luke

AU - Ikonomidis, J. S.

AU - Feldman, D. S.

PY - 2004

Y1 - 2004

N2 - Introduction. CD3 monitoring of antithymocyte globulin therapy in renal transplantation has been shown to be more cost-effective than standard regimens. The objective of this study was to evaluate CD3 monitoring with Thymoglobulin in cardiac transplantation. Methods. Cardiac transplant patients who required antithymocyte globulin therapy were dose-adjusted to maintain absolute CD3 counts <25 cells/μL. Endomyocardial biopsies and hemodynamic parameters were used to assess efficacy. The incidences of hematological side effects, opportunistic infections, and malignancies were recorded; in addition we performed a cost comparison. Results. Eight patients were treated with Thymoglobulin using CD3 monitoring to adjust the dosing. All patients responded with few side effects. Compared to standard dosing, CD3 monitoring allowed a 60% reduction in the average total dose and a 58% reduction in cost per patient. Conclusion. CD3 monitoring of Thymoglobulin therapy in cardiac transplant patients results in lower doses and reduced costs with equivalent efficacy and a low incidence of complications.

AB - Introduction. CD3 monitoring of antithymocyte globulin therapy in renal transplantation has been shown to be more cost-effective than standard regimens. The objective of this study was to evaluate CD3 monitoring with Thymoglobulin in cardiac transplantation. Methods. Cardiac transplant patients who required antithymocyte globulin therapy were dose-adjusted to maintain absolute CD3 counts <25 cells/μL. Endomyocardial biopsies and hemodynamic parameters were used to assess efficacy. The incidences of hematological side effects, opportunistic infections, and malignancies were recorded; in addition we performed a cost comparison. Results. Eight patients were treated with Thymoglobulin using CD3 monitoring to adjust the dosing. All patients responded with few side effects. Compared to standard dosing, CD3 monitoring allowed a 60% reduction in the average total dose and a 58% reduction in cost per patient. Conclusion. CD3 monitoring of Thymoglobulin therapy in cardiac transplant patients results in lower doses and reduced costs with equivalent efficacy and a low incidence of complications.

UR - http://www.scopus.com/inward/record.url?scp=21244477194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244477194&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2004.11.099

DO - 10.1016/j.transproceed.2004.11.099

M3 - Article

C2 - 15686739

AN - SCOPUS:21244477194

VL - 36

SP - 3245

EP - 3249

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -